Cerebrolysin
Also known as: Peptide Neurotrophic Preparation
Overview
Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from porcine brain tissue. It is used as a medicine in some countries for stroke, traumatic brain injury, and dementia-related contexts, but availability and licensing vary widely.
How it works
Contains neurotrophic peptide fragments that may mimic or support neurotrophic factor signalling. Proposed mechanisms include reduced excitotoxicity, improved neuronal survival, enhanced neuroplasticity, and modulation of inflammatory and apoptotic pathways.
Primary uses
- Neurorecovery research
- Stroke treatment context
- Traumatic brain injury research
- Cognitive decline research
- Neuroplasticity
What to expect
Based on reported user experiences and available research, here is a general timeline of effects:
Days 1–7
- Neuroprotective effects begin from the first dose
- Some users report improved mental clarity within the first week
- BDNF and NGF upregulation is active immediately
Days 7–28
- Cognitive function and memory improvements are becoming noticeable
- Neuroplasticity and synapse formation are progressing
- Mood and focus improvements are commonly reported by week 2
Days 28–999
- Significant neuroprotective and cognitive benefits are established at 4+ weeks
- Long-term use is supported by extensive clinical data
- Consider a rest period after your current cycle before repeating
Storage and preparation
Store ampoules according to manufacturer labelling, typically protected from light and not frozen unless specified. Do not use if solution is cloudy or ampoule integrity is compromised.
Usually supplied as a ready-to-use injectable solution rather than a lyophilised vial. It should not be reconstituted unless using a formulation specifically supplied for that purpose.
Track your compound stack in Lymity
Log doses, track cycles, and see your timeline benefits in the app